Success of targeted transperineal biopsy in patients on surveillance for grade group 1 prostate cancer

Authors

  • Kevin Martell University of Calgary
  • Hans Chung Department of Radiation Oncology, Sunnybrook Health Sciences Centre, University of Toronto
  • Gerard Morton Department of Radiation Oncology, Sunnybrook Health Sciences Centre, University of Toronto
  • Danny Vesprini Department of Radiation Oncology, Sunnybrook Health Sciences Centre, University of Toronto
  • Chia-Lin Tseng Department of Radiation Oncology, Sunnybrook Health Sciences Centre, University of Toronto
  • Ewa Szumacher Department of Radiation Oncology, Sunnybrook Health Sciences Centre, University of Toronto
  • Patrick Cheung Department of Radiation Oncology, Sunnybrook Health Sciences Centre, University of Toronto
  • Will Chu Department of Radiation Oncology, Sunnybrook Health Sciences Centre, University of Toronto
  • Stanley Liu Department of Radiation Oncology, Sunnybrook Health Sciences Centre, University of Toronto
  • Andrew Loblaw Department of Radiation Oncology, Sunnybrook Health Sciences Centre, University of Toronto

DOI:

https://doi.org/10.5489/cuaj.7752

Keywords:

prostate cancer, targeted biopsy, transperineal biopsy

Abstract

Introduction: We aimed to determine the minimum cross-sectional ellipsoid area on magnetic resonance (MR) of intraprostatic nodules that best predicts for subsequent targeted biopsies revealing ≥ grade group (GG) 2 disease.

Methods: Forty-six patients previously diagnosed with GG 1 prostate adenocarcinoma who received cognitively fused, MR-guided, transperineal targeted biopsies in addition to six random biopsies were included in this analysis. A Youden cutpoint analysis was used to determine the ellipsoid area in the axial plane best predicting for ≥GG 2 disease within the targeted biopsy cores and logistic regression used to assess the result.

Results: Median time from MR imaging to targeted biopsy was 2.4 (1.4–5.5) months. Forty of 46 (87%) patients had one nodule and 6/46 (13%) had two separate nodules on MR that received targeted biopsy. Of the 52 nodules, five (10%), 33 (63%), and 14 (27%) were Prostate Imaging-Reporting and Data System (PI-RADS) 3, 4, and 5, respectively. Thirteen (25%), six (12%), and 33 (64%) were in the anterior, medial, and posterior regions of the prostate, respectively. Median area was 0.72 (0.49–1.29) cm2 (average diameter 9.5 mm). Fifteen of 46 (33%) patients had ≥1 random biopsy and 20/52 (38%) nodules had ≥1 targeted biopsy revealing ≥GG 2 disease. The optimal area cutpoint was ≥0.7 cm2, with an area under the curve of 0.671 (0.510–0.832). On logistic regression, area ≥0.7 cm2 was solely predictive of targeted biopsy revealing ≥GG 2 disease (odds ratio 6.5, 1.3–32.4, p=0.022).

Conclusions: Nodule area ≥0.7 cm2 may predict for transperineal-based targeted biopsies being positive for ≥GG 2 disease when 1–2 cores are taken.

Downloads

Download data is not yet available.

Downloads

Published

2022-03-11

How to Cite

Martell, K., Chung, H. ., Morton, G. ., Vesprini, D. ., Tseng, C.-L. ., Szumacher, E. ., Cheung, P. ., Chu, W. ., Liu, S. ., & Loblaw, A. . (2022). Success of targeted transperineal biopsy in patients on surveillance for grade group 1 prostate cancer. Canadian Urological Association Journal, 16(8), E437–42. https://doi.org/10.5489/cuaj.7752

Issue

Vol. 16 No. 8 (2022): CUAJ August

Section

Original Research

License

You, the Author(s), assign your copyright in and to the Article to the Canadian Urological Association. This means that you may not, without the prior written permission of the CUA:

  • Post the Article on any Web site
  • Translate or authorize a translation of the Article
  • Copy or otherwise reproduce the Article, in any format, beyond what is permitted under Canadian copyright law, or authorize others to do so
  • Copy or otherwise reproduce portions of the Article, including tables and figures, beyond what is permitted under Canadian copyright law, or authorize others to do so.

The CUA encourages use for non-commercial educational purposes and will not unreasonably deny any such permission request.

You retain your moral rights in and to the Article. This means that the CUA may not assert its copyright in such a way that would negatively reflect on your reputation or your right to be associated with the Article.

The CUA also requires you to warrant the following:

  • That you are the Author(s) and sole owner(s), that the Article is original and unpublished and that you have not previously assigned copyright or granted a licence to any other third party;
  • That all individuals who have made a substantive contribution to the article are acknowledged;
  • That the Article does not infringe any proprietary right of any third party and that you have received the permissions necessary to include the work of others in the Article; and
  • That the Article does not libel or violate the privacy rights of any third party.